MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Treprostinil

CAS No. : 81846-19-7

MCE 站：Treprostinil

产品活性：Treprostinil (LRX-15) 是高效的DP1和EP2激动剂，其EC₅₀值分别为0.6±0.1和6.2±1.2 nM。

研究领域：GPCR/G Protein

作用靶点：Prostaglandin Receptor

In Vitro: Treprostinil has high affinity for the DP1, EP2 and IP receptors (K_i=4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells.

In Vivo: Inhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH). Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels.Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Prostaglandin E2  |  Prostaglandin E1  |  Iloprost  |  PF-04418948  |  Tranilast  |  ONO-AE3-208  |  AH 6809  |  U-46619  |  Latanoprost  |  Laropiprant  |  Rebamipide  |  Travoprost  |  RO1138452  |  Ramatroban  |  p-Hydroxycinnamic acid  |  Bimatoprost  |  Pectolinarin  |  Taprenepag  |  Dinoprost tromethamine salt  |  (+)-Cloprostenol  |  Dazoxiben  |  Evatanepag  |  L-798106  |  Seratrodast  |  Nedocromil  |  CAY10471 Racemate  |  Cloprostenol sodium salt  |  L 888607  |  AZ12672857  |  Prostaglandin D2

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。